LAUSR

BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab.

Sign Up to like & get
recommendations!
1 Published in 2020 at "Multiple sclerosis and related disorders"

DOI: 10.1016/j.msard.2020.102186

Abstract: OBJECTIVES Ocrelizumab (OCR) is a humanized monoclonal antibody targeting CD20 antigen exposed on B cells surface. Kinetic of B-cells repopulation after depletion therapy shows high intra and inter-individual variability. The aim of this study was… read more here.

Keywords: sclerosis; treatment; repopulation; multiple sclerosis ... See more keywords